ATLAS News · Regulation

Wisconsin Joins Federal Lawsuit Against Hims & Hers Health

· 2 sources

Wisconsin is joining a federal lawsuit against telehealth provider Hims & Hers Health, WPR reports. The Motley Fool also cites weak company guidance.

What happened

Wisconsin is joining a federal lawsuit against the telehealth provider Hims & Hers Health, according to WPR. The company offers widely advertised direct-to-consumer treatments.

WPR says those treatments cover hair loss, weight loss and erectile dysfunction. The sources provided do not detail the claims in the lawsuit.

Separately, The Motley Fool reports that Hims & Hers stock fell 17% after the company issued weak guidance. The outlet also refers to an upcoming peptide push.

Context

Telehealth companies that sell treatments directly to consumers operate in an area that draws regulatory and legal attention.

Why it matters

A new government participant in a federal lawsuit may add legal uncertainty for Hims & Hers Health, alongside the investor focus on its guidance.

Stocks in this story

Price changes are shown for the trading day of the story and are a coincidence in time, not proof that the news caused them. Figures are ATLAS data from our database.

Healthcare · NYSE

Live price
$19.89▲ +0.86%

live price · USD

Latest price during the session
$19.89+0.86% vs. previous close ($19.72)
Fair value (ATLAS)
$25.75Fair range: $5.83 to $42.25The price ($19.89) is 22.8% below that figure.
Chance of a rise in 1 month
44%Probability of closing higher than today within 21 sessions.Normal range: half of the scenarios end between $15.90 and $22.92; 9 in 10, between $11.50 and $31.69.
See the full ATLAS analysis of Hims & Hers Health →

Closing prices, fair value and probabilities: ATLAS own data. How we calculate fair value.

Sources

ATLAS writes its own summaries from the reporting of these outlets. Each link opens the original publisher.

  1. Wisconsin joins federal lawsuit against Hims & Hers telehealth provider · WPR · November 13, 2026
  2. Hims & Hers Stock Just Plummeted 17%. Is the Stock a Buy Ahead of a Peptide Push? · The Motley Fool · November 13, 2026

Related

Latest market news · Markets today on ATLAS · Hims & Hers Health

What you get with ATLAS

Create my ATLAS account →

Fair value, probabilities and earnings for every stock. Free account, no card. Information, not advice.

Information, not advice. This content is informational and is not an investment recommendation or an offer to buy or sell securities. ATLAS estimates come from statistical models using public data, can be wrong, and past performance does not guarantee future results. Disclaimer

ATLAS Signals

ATLAS Signals, every week

The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.

By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy